Literature DB >> 8573160

The Vpr protein of human immunodeficiency virus type 1 binds to nucleocapsid protein p7 in vitro.

M S Li1, G Garcia-Asua, U Bhattacharyya, P Mascagni, B M Austen, M M Roberts.   

Abstract

The Vpr protein of human immunodeficiency virus type 1 (HIV-1) is incorporated into the virion by the Gag polyprotein precursor Pr55gag. The importance of the p6gag sequence at the C-terminal end of Pr55gag has a crucial role in Vpr incorporation. To identify the Gag sequences directly involved in Vpr binding, we compared the Vpr binding affinities of the 71 amino acid nucleocapsid protein p7, the C-terminal peptide (35-71) p7C and p6gag by affinity chromatography. p7 and p7C have the strongest Vpr binding activities compared to p6gag. These results suggest that the nucleocapsid protein and its C-terminal domain may be important for the incorporation of Vpr into the mature HIV-1 virion and the subsequent localisation of viral nucleic acid to the cell nucleus by Vpr.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8573160     DOI: 10.1006/bbrc.1996.0061

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Biochemical analyses of the interactions between human immunodeficiency virus type 1 Vpr and p6(Gag).

Authors:  Y Jenkins; O Pornillos; R L Rich; D G Myszka; W I Sundquist; M H Malim
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

2.  Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease.

Authors:  N Sheng; S C Pettit; R J Tritch; D H Ozturk; M M Rayner; R Swanstrom; S Erickson-Viitanen
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain.

Authors:  M A Accola; B Strack; H G Göttlinger
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 4.  HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-29       Impact factor: 11.056

Review 5.  Protein intrinsic disorder as a flexible armor and a weapon of HIV-1.

Authors:  Bin Xue; Marcin J Mizianty; Lukasz Kurgan; Vladimir N Uversky
Journal:  Cell Mol Life Sci       Date:  2011-10-28       Impact factor: 9.261

6.  Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor.

Authors:  M Bouyac; M Courcoul; G Bertoia; Y Baudat; D Gabuzda; D Blanc; N Chazal; P Boulanger; J Sire; R Vigne; B Spire
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

7.  A protein ballet around the viral genome orchestrated by HIV-1 reverse transcriptase leads to an architectural switch: from nucleocapsid-condensed RNA to Vpr-bridged DNA.

Authors:  Sébastien Lyonnais; Robert J Gorelick; Fatima Heniche-Boukhalfa; Serge Bouaziz; Vincent Parissi; Jean-François Mouscadet; Tobias Restle; Jose Maria Gatell; Eric Le Cam; Gilles Mirambeau
Journal:  Virus Res       Date:  2012-09-24       Impact factor: 3.303

8.  Human immunodeficiency virus type 1 Vpr protein is incorporated into the virion in significantly smaller amounts than gag and is phosphorylated in infected cells.

Authors:  B Müller; U Tessmer; U Schubert; H G Kräusslich
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

9.  Mutations in the N-terminal domain of human immunodeficiency virus type 1 nucleocapsid protein affect virion core structure and proviral DNA synthesis.

Authors:  L Berthoux; C Péchoux; M Ottmann; G Morel; J L Darlix
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

10.  Interaction with the p6 domain of the gag precursor mediates incorporation into virions of Vpr and Vpx proteins from primate lentiviruses.

Authors:  L Selig; J C Pages; V Tanchou; S Prévéral; C Berlioz-Torrent; L X Liu; L Erdtmann; J Darlix; R Benarous; S Benichou
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.